4 Results for "

H22 cells

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "H22 cells" in MCE Product Catalog:

Cat. No.: HY-161141
CAS No.: 2761180-01-0
Target:  

c-Met/HGFR

Research Areas:  

Cancer

EGFR/ C-Met-in-2 (Compound H-22) is a dual inhibitor of EGFR/c-Met. EGFR/c-Met-IN-2 inhibits cell proliferation by arresting G2/M phase. EGFR/c-Met-IN-2 has antitumor activity .
loading...
    loading...
Cat. No.: HY-172108
Target:  

TGF-β Receptor

Research Areas:  

Cancer

TGFβRI-IN-7 (compound 16W) is a potent inhibitor of TGFβRI. TGFβRI-IN-7 inhibits SMAD2/3 phosphorylation and H22 cell viability with IC50 values of 12 and 65 nM, respectively. TGFβRI-IN-7 shows anti-tumor efficacy in a xenograft model of H22 cells, with TGI of 79.6 % .
loading...
    loading...
Cat. No.: HY-144232
CAS No.: 2768083-57-2
Target:  

Others

Research Areas:  

Cancer

Anticancer agent 28 shows good antitumor activity in H22 allogeneic mice in vivo. Anticancer agent 28 has inhibitory potency in K562 cells of 50 times than oridonin, and its IC50 value is 0.09 μM.
loading...
    loading...
Cat. No.: HY-182447
CAS No.: 69095-83-6
Synonyms: DL111-IT
Target:  

CDK Apoptosis

Research Areas:  

Endocrinology Cancer

Contragestazol (DL111-IT) is a non-hormonal antifertility agent. Contragestazol reduces the expression of Cyclin D1 and CDK4, increases the expression of total retinoblastoma protein (pRb), and decreases the level of hyperphosphorylated pRb. Contragestazol induces G0/G1 phase cell cycle arrest. Contragestazol inhibits embryonic development by inducing luteal cell apoptosis and reducing intrauterine polyamine levels. Contragestazol exhibits antitumor activity against prostate cancer, S180 tumor and H22 tumor. Contragestazol shows extremely potent activity in terminating early pregnancy in animals .
loading...
    loading...